Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
ALK translocation
i
Other names:
NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
238
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
ALK amplification (3)
ALK amplification (3)
›
Related tests:
Lung Cancer 8-Gene Kit
Lung Cancer 8-Gene Kit
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
ALK translocation
Soft Tissue Sarcoma
ALK translocation
Soft Tissue Sarcoma
crizotinib
Sensitive: A2 - Guideline
crizotinib
Sensitive
:
A2
crizotinib
Sensitive: A2 - Guideline
crizotinib
Sensitive
:
A2
ALK translocation
Soft Tissue Sarcoma
ALK translocation
Soft Tissue Sarcoma
brigatinib
Sensitive: A2 - Guideline
brigatinib
Sensitive
:
A2
brigatinib
Sensitive: A2 - Guideline
brigatinib
Sensitive
:
A2
ALK translocation
Soft Tissue Sarcoma
ALK translocation
Soft Tissue Sarcoma
ceritinib
Sensitive: A2 - Guideline
ceritinib
Sensitive
:
A2
ceritinib
Sensitive: A2 - Guideline
ceritinib
Sensitive
:
A2
ALK translocation
Soft Tissue Sarcoma
ALK translocation
Soft Tissue Sarcoma
lorlatinib
Sensitive: A2 - Guideline
lorlatinib
Sensitive
:
A2
lorlatinib
Sensitive: A2 - Guideline
lorlatinib
Sensitive
:
A2
ALK translocation
Non Small Cell Lung Cancer
ALK translocation
Non Small Cell Lung Cancer
Sensitive: B - Late Trials
Sensitive
:
B
Sensitive: B - Late Trials
Sensitive
:
B
ALK translocation
Non Small Cell Lung Cancer
ALK translocation
Non Small Cell Lung Cancer
tislelizumab-jsgr
Sensitive: C2 – Inclusion Criteria
tislelizumab-jsgr
Sensitive
:
C2
tislelizumab-jsgr
Sensitive: C2 – Inclusion Criteria
tislelizumab-jsgr
Sensitive
:
C2
ALK translocation
Non Small Cell Lung Cancer
ALK translocation
Non Small Cell Lung Cancer
durvalumab
Sensitive: C2 – Inclusion Criteria
durvalumab
Sensitive
:
C2
durvalumab
Sensitive: C2 – Inclusion Criteria
durvalumab
Sensitive
:
C2
ALK translocation
Non Small Cell Lung Cancer
ALK translocation
Non Small Cell Lung Cancer
crizotinib
Sensitive: C2 – Inclusion Criteria
crizotinib
Sensitive
:
C2
crizotinib
Sensitive: C2 – Inclusion Criteria
crizotinib
Sensitive
:
C2
ALK translocation
Non Small Cell Lung Cancer
ALK translocation
Non Small Cell Lung Cancer
ALK inhibitor
Sensitive: C4 – Case Studies
ALK inhibitor
Sensitive
:
C4
ALK inhibitor
Sensitive: C4 – Case Studies
ALK inhibitor
Sensitive
:
C4
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.